Delaware
|
3826
|
26-1756290
|
(State or other jurisdiction of incorporation or
|
(Primary Standard Industrial
|
(I.R.S. Employer
|
organization)
|
Classification Code Number)
|
Identification No.)
|
Thomas A. Coll, Esq.
|
R. Erik Holmlin, Ph.D.
|
Ivan K. Blumenthal, Esq.
|
James C. Pennington, Esq.
|
President and Chief Executive Officer
|
Cliff M. Silverman, Esq.
|
Cooley LLP
|
Bionano Genomics, Inc.
|
Mintz, Levin, Cohn, Ferris, Glovsky
|
4401 Eastgate Mall
|
9540 Towne Centre Drive, Suite 100
|
and Popeo, P.C.
|
San Diego, California 92121
|
San Diego, California 92121
|
Chrysler Center
|
(858) 550-6000
|
(858) 888-7600
|
666 Third Avenue
|
New York, NY 10017
|
||
(212) 935-3000
|
||
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☒
|
Title of Each Class of Securities to be Registered
|
Proposed Maximum
Aggregate
Offering Price(1)(4)
|
Amount of Registration Fee(1)
|
||||||
Common Stock, par value $0.0001 per share(2)(3)
|
$
|
2,999,200
|
||||||
Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof(2)(3)
|
$
|
2,999,200
|
||||||
Warrants to purchase Common Stock and shares of Common Stock issuable upon exercise thereof(2)
|
$
|
2,999,200
|
||||||
Total
|
$
|
5,998,400
|
$
|
779
|
(1) |
Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the
“Securities Act”).
|
(2) |
Pursuant to Rule 416 under the Securities Act of 1933, as amended, the securities being registered hereunder include such indeterminate number of additional
securities as may be issuable to prevent dilution resulting from stock splits, dividends or similar transactions.
|
(3) |
The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the
aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum
offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $2,999,200.
|
(4) |
The securities being registered pursuant to this Registration Statement are in addition to the $15,000,980 of common stock, $15,000,980 of pre-funded warrants to
purchase shares of common stock and common stock issuable upon exercise thereof and $15,000,980 warrants to purchase common stock and shares of common stock issuable upon exercise thereof, registered pursuant to the Registrant’s
Registration Statement on Form S-1 (Registration No. 333-237074).
|
Exhibit
Number
|
Description
|
|
Opinion of Cooley LLP.
|
||
Consent of Deloitte & Touche LLP, an Independent Registered Public Accounting Firm.
|
||
Consent of Cooley LLP (included in Exhibit 5.1).
|
||
Power of Attorney (included on the signature page of the Registration Statement on Form S-1, as amended (File No. 333-237074), filed with the Securities and Exchange Commission on March
11, 2020 and incorporated herein by reference).
|
BIONANO GENOMICS, INC.
|
||
By:
|
/s/ R. Erik Holmlin, Ph.D.
|
|
R. Erik Holmlin, Ph.D.
|
||
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
||
/s/ R. Erik Holmlin, Ph.D.
|
Chief Executive Officer and Director
|
April 1, 2020
|
||
R. Erik Holmlin, Ph.D.
|
||||
(Principal Executive and Financial Officer)
|
|
|||
/s/ Mark Adamchak
|
Controller
|
April 1, 2020
|
||
Mark Adamchak
|
||||
(Principal Accounting Officer)
|
|
|||
/s/ David L. Barker, Ph.D.*
|
||||
David L. Barker, Ph.D.
|
Director
|
April 1, 2020
|
||
/s/ Albert A. Luderer, Ph.D.*
|
||||
Albert A. Luderer, Ph.D.
|
Director
|
April 1, 2020
|
||
/s/ Junfeng Wang*
|
||||
Junfeng Wang
|
Director
|
April 1, 2020
|
||
/s/ Christopher Twomey*
|
Director |
|||
Christopher Twomey
|
|
April 1, 2020
|
||
/s/ Kristina Vuori, M.D., Ph.D.*
|
Director | |||
Kristiina Vuori, M.D., Ph.D.
|
|
April 1, 2020
|
*
|
Pursuant to Power of Attorney | |
By:
|
/s/ R. Erik Holmlin, Ph.D.
|
|
R. Erik Holmlin, Ph.D.
|
||
Attorney-in-Fact
|
By: |
/s/ Thomas A. Coll |
|
|
Thomas A. Coll | |
|
|